Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

Main Article Content

Paul Telfer *
Irene Agodoa
Kathleen M. Fox
Laurie Burke
Timothy Mant
Marzena Jurek
Margaret Tonda
Josh Lehrer-Graiwer
(*) Corresponding Author:
Paul Telfer | paul.telfer@bartshealth.nhs.uk

Abstract

For many patients with sickle cell disease (SCD), jaundice is a significant clinical disease manifestation that impacts on patient well-being. We report a case of a patient with SCD and chronic jaundice treated with voxelotor (GBT440), a novel small molecule hemoglobin oxygen affinity modulator and potential disease-modifying therapy for SCD. The case patient is a 27- year-old Black male with a long history of SCD with clinical jaundice and scleral icterus. After starting voxelotor, the patient reported that his jaundice cleared within one week, and that he felt much better with more energy, and was relieved after his eyes cleared. Voxelotor reduced bilirubin and unconjugated bilirubin (by up to 76%), and hemoglobin improved from 9.9 g/dL at baseline to 11.1 g/dL at 90 days. Jaundice impacts many adults with SCD, significantly impacting self-image. Voxelotor treatment reduced bilirubin levels and improved jaundice, resulting in an improved sense of well-being in our case patient.

Downloads month by month

Downloads

Download data is not yet available.

Article Details